Halitosis vaccines targeting FomA, a biofilm-bridging protein of fusobacteria nucleatum
- PMID: 23865430
- DOI: 10.2174/15665240113139990063
Halitosis vaccines targeting FomA, a biofilm-bridging protein of fusobacteria nucleatum
Abstract
Halitosis (bad breath) is estimated to influence more than half of the world's population with varying degree of intensity. More than 85% of halitosis originates from oral bacterial infections. Foul-smelling breath mainly results from bacterial production of volatile sulfur compounds (VSCs) such as hydrogen sulfide and methyl mercaptan. To date, major treatments for elimination of oral malodor include periodontal therapy combined with antibiotics or antimicrobial agents, and mechanical approaches including tooth and tongue cleaning. These treatments may transiently reduce VSCs but carry risks of generating toxicity, increasing resistant strains and misbalancing the resident human flora. Therefore, there is a need to develop alternative therapeutic modalities for halitosis. Plaque biofilms are the principal source for generating VSCs which are originally metabolized from amino acids during co-aggregation of oral bacteria. Blocking the bacterial coaggregation, therefore, may prevent various biofilm-associated oral diseases such as periodontitis and halitosis. Fusobacterium nucleatum (F. nucleatum), a Gram-negative anaerobe oral bacterium, is a main bacterial strain related to halitosis. Aggregation of F. nucleatum with other bacteria to form plaque biofilms in oral cavity causes bad breath. FomA, the major outer membrane protein of F. nucleatum, recruits other oral pathogenic bacteria such as Porphyromonas gingivalis (P. gingivalis) in the periodontal pockets. A halitosis vaccine targeting F. bacterium FomA significantly abrogates the enhancement of bacterial co-aggregation, biofilms, production of VSCs, and gum inflammation mediated by an inter-species interaction of F. nucleatum with P. gingivalis, which suggests FomA of F. nucleatum to be a potential target for development of vaccines or drugs against bacterial biofilm formation and its associated pathogenicities.
Similar articles
-
Vaccination targeting surface FomA of Fusobacterium nucleatum against bacterial co-aggregation: Implication for treatment of periodontal infection and halitosis.Vaccine. 2010 Apr 26;28(19):3496-505. doi: 10.1016/j.vaccine.2010.02.047. Epub 2010 Feb 26. Vaccine. 2010. PMID: 20189489 Free PMC article.
-
A novel vaccine targeting Fusobacterium nucleatum against abscesses and halitosis.Vaccine. 2009 Mar 4;27(10):1589-95. doi: 10.1016/j.vaccine.2008.12.058. Epub 2009 Jan 20. Vaccine. 2009. PMID: 19162109 Free PMC article.
-
Cetylpyridinium chloride suppresses gene expression associated with halitosis.Arch Oral Biol. 2013 Nov;58(11):1686-91. doi: 10.1016/j.archoralbio.2013.08.014. Epub 2013 Sep 6. Arch Oral Biol. 2013. PMID: 24112735
-
The relationship between oral malodor and volatile sulfur compound-producing bacteria.Otolaryngol Head Neck Surg. 2006 Nov;135(5):671-6. doi: 10.1016/j.otohns.2005.09.036. Otolaryngol Head Neck Surg. 2006. PMID: 17071291 Review.
-
Extra-oral halitosis: an overview.J Breath Res. 2010 Mar;4(1):017003. doi: 10.1088/1752-7155/4/1/017003. Epub 2010 Mar 2. J Breath Res. 2010. PMID: 21386205 Review.
Cited by
-
Evaluation of the antibacterial activity of Elsholtzia ciliate essential oil against halitosis-related Fusobacterium nucleatum and Porphyromonas gingivalis.Front Microbiol. 2023 Aug 7;14:1219004. doi: 10.3389/fmicb.2023.1219004. eCollection 2023. Front Microbiol. 2023. PMID: 37608950 Free PMC article.
-
Fusobacterium nucleatum: a new player in regulation of cancer development and therapeutic response.Cancer Drug Resist. 2022 May 12;5(2):436-450. doi: 10.20517/cdr.2021.144. eCollection 2022. Cancer Drug Resist. 2022. PMID: 35800370 Free PMC article. Review.
-
The role of oral microbiome in pemphigus vulgaris.Arch Microbiol. 2021 Jul;203(5):2237-2247. doi: 10.1007/s00203-021-02199-5. Epub 2021 Feb 26. Arch Microbiol. 2021. PMID: 33634320
-
The role of Fusobacterium nucleatum in colorectal cancer: from carcinogenesis to clinical management.Chronic Dis Transl Med. 2019 Oct 1;5(3):178-187. doi: 10.1016/j.cdtm.2019.09.001. eCollection 2019 Sep. Chronic Dis Transl Med. 2019. PMID: 31891129 Free PMC article.
-
Fusobacterium nucleatum - symbiont, opportunist and oncobacterium.Nat Rev Microbiol. 2019 Mar;17(3):156-166. doi: 10.1038/s41579-018-0129-6. Nat Rev Microbiol. 2019. PMID: 30546113 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials